Moody's believes Shire plc's announcement that it is evaluating strategic options for its neurosciences franchise could lead to changes having negative credit implications.

The rating agency believes a separation of the unit would reduce Shire's scale, diversity and earnings. There is no impact on the company's Baa3 rating or the stable rating outlook.